Core Insights - Capricor Therapeutics has announced new data on a scalable framework for loading therapeutic siRNAs and PMOs into exosomes, which is crucial for future clinical development [1][2][4] Group 1: Exosome Technology - The poster presented at the AAEV 2025 highlighted Capricor's proprietary exosome-based technology, showcasing strategies for scale-up and scale-out electroporation to achieve larger yields of engineered exosomes [2][4] - Key findings indicate that engineered exosomes derived from 293F cells can be successfully loaded with therapeutic siRNA and PMO using optimized electroporation conditions, with comparable loading efficiencies to standard methods [7] Group 2: Clinical Development - Establishing a scalable and reproducible loading process is essential for advancing Capricor's exosome pipeline for therapeutic development [4] - The framework developed provides a feasible pathway for producing clinically relevant quantities of loaded exosomes to support future clinical development [7] Group 3: Company Overview - Capricor Therapeutics is focused on advancing cell and exosome-based therapeutics, with its lead product candidate, Deramiocel, in late-stage clinical development for Duchenne muscular dystrophy (DMD) [5][9] - The company is leveraging its proprietary StealthX™ platform for preclinical development aimed at targeted delivery of therapeutics, with potential applications across a wide range of diseases [5]

Core Points - Schouw & Co. initiated a share buy-back programme on 5 May 2025, with a total budget of DKK 120 million for the period from 5 May to 31 December 2025 [1] - The buy-back programme complies with EU regulations on market abuse and follows the "Safe Harbour" rules [1] Summary by Relevant Sections Share Buy-Back Programme - The programme aims to acquire shares worth up to DKK 120 million [1] - The buy-back period is set from 5 May to 31 December 2025 [1] Trading Activity - As of 14 November 2025, Schouw & Co. accumulated 182,100 shares at an average price of DKK 598.21, totaling DKK 108,934,418 [2] - From 17 November to 21 November 2025, the company bought an additional 7,100 shares at an average price of DKK 578.62, amounting to DKK 4,108,177 [2] - By 21 November 2025, the total number of shares acquired reached 189,200, with an average price of DKK 597.48, totaling DKK 113,042,595 [2] Treasury Shares - Following the buy-back transactions, Schouw & Co. holds a total of 2,231,193 treasury shares, representing 8.92% of the total share capital of 25,000,000 shares [2]

Core Viewpoint - The Company, ŽEMAITIJOS PIENAS, AB, has announced a share buyback program following the approval from its Annual General Meeting of Shareholders, with a total maximum acquisition value of EUR 2.4 million [1][2] Group 1: Share Buyback Details - The acquisition of ordinary registered shares will occur through Nasdaq CSD SE, with a nominal value of EUR 0.29 per share [1] - The buyback period is set to start on 26 November 2025 and end on 3 December 2025 [2] - The maximum number of shares to be acquired is 1,000,000 units, with an acquisition price of EUR 2.40 per share [2] Group 2: Shareholder Participation - Orders to sell shares will be accepted throughout the entire buyback period, and if the total number of tendered shares exceeds the maximum number, the shares sold by each shareholder will be reduced on a pro rata basis [1]

Core Points - Ukraine becomes the first European country to launch Starlink's Direct to Cell satellite technology, enabling connectivity for customers in remote areas [1][3][7] - The service will initially provide SMS capabilities, with plans to expand to voice and data by 2026, supporting both individuals and businesses [2][5] - The launch is part of a broader commitment by VEON and Kyivstar to enhance connectivity in Ukraine, especially during wartime challenges [3][4][7] Company Overview - VEON Ltd. operates as a global digital operator, providing connectivity and digital services to nearly 150 million users across five countries [8] - Kyivstar Group Ltd. serves over 22.5 million mobile customers and is a leading digital operator in Ukraine, offering a range of services including 4G and cloud solutions [9] - Both companies plan to invest USD 1 billion in Ukraine from 2023 to 2027 for infrastructure and technological development [10] Technology and Service Details - Starlink Direct to Cell is the largest satellite constellation with over 650 satellites, designed to provide connectivity in mobile dead zones [11] - The service allows existing 4G smartphones to connect without additional costs, covering most of Ukraine except for occupied and combat zones [7][11]

Urbo bankas UAB (hereinafter - “the Bank”), company code 112027077, address: Konstitucijos pr.18B, Vilnius. In the first three quarters of this year, Lithuania-based Urbo Bankas recorded double-digit growth in both its loan and deposit portfolios. Year-to-date, the bank’s loans have grown by more than 26% (from EUR 414.5 million) and deposits by 22% (from EUR 557.3 million). “This year, we have continued our consistent growth in both deposit and loan categories. In order to strengthen the bank’s capital ba ...

Core Insights - YD Bio Limited has achieved significant regulatory and clinical milestones, marking its first commercial entry into the U.S. eye care market with exosome-based therapeutics [1][4] - The Exovisse Contact Lenses have received FDA 510(k) clearance as a Class II medical device, allowing for legal marketing in the U.S. [1][2] - Exovisse Artificial Tears have been developed in compliance with the FDA OTC Final Monograph M018, enabling nationwide over-the-counter distribution [1][2] Regulatory Achievements - The 510(k) clearance confirms that Exovisse Contact Lenses are substantially equivalent to an already marketed device, facilitating their sale in the U.S. [2] - Compliance with the OTC monograph for Exovisse Artificial Tears ensures they meet established safety and labeling requirements, allowing for marketing without individual FDA premarket approval [2] Clinical Development - YD Bio and 3D Global Biotech are planning a small clinical trial in Taiwan to evaluate dry eye disease, collaborating with YC Biotech [3] - The company is advancing LSC Exosome Therapeutics through collaboration with 3D Global Biotech, focusing on applications for retinal and macular disorders [3] Strategic Vision - The achievements signify YD Bio's transition from laboratory innovation to patient-ready products, establishing a commercial foundation in ophthalmology [4] - The company aims to provide everyday eye care products in the U.S., indicating a pragmatic path from development to revenue in a high-demand market [4] Company Overview - YD Bio Limited is focused on advancing clinical trials, new drug development, and therapies for diseases with high unmet medical needs [5] - The company is committed to improving patient outcomes through scientific innovation and precision medicine, and has expanded into the development and distribution of post-market auxiliary products [5]

Core Viewpoint - FibroBiologics, Inc. has announced a registered direct offering of 4,477,614 shares of common stock at $0.335 per share, along with a concurrent private placement of unregistered warrants for the same number of shares at the same exercise price, aiming to raise approximately $1.5 million in gross proceeds [1][3]. Group 1: Offering Details - The offering consists of 4,477,614 shares of common stock priced at $0.335 each, with a concurrent issuance of unregistered warrants to purchase the same number of shares at the same price [1]. - The closing of the offering is expected around November 25, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2]. Group 2: Financial Implications - The total gross proceeds from the offering are anticipated to be approximately $1.5 million before deducting fees and expenses [3]. - If the unregistered warrants are fully exercised, an additional gross proceeds of approximately $1.5 million could be realized [3]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes [3]. Group 3: Regulatory Information - The shares are being offered under a "shelf" registration statement on Form S-3, which became effective on February 10, 2025 [4]. - The unregistered warrants and shares from the private placement are offered under Section 4(a)(2) of the Securities Act and have not been registered [5]. Group 4: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells, holding over 270 patents [9]. - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, and cancer, representing advancements in cell therapy and tissue regeneration [9].

Core Insights - Digerati Technologies has successfully acquired Ricochet Global, enhancing its capabilities in telecommunications services, particularly in Africa, the Middle East, and the Persian Gulf [1][2]. Company Overview - Digerati Technologies operates as a holding company and provides co-location and technology infrastructure solutions through its subsidiary, WaivCloud, Inc. [4]. - WaivCloud focuses on delivering secure, reliable, and scalable data center solutions, emphasizing exceptional customer service and personalized support [4]. Acquisition Details - The acquisition of Ricochet was executed through a combination of cash and restricted common stock [2]. - Ricochet is recognized for its advanced switching and routing architecture, which ensures high-quality service while maintaining efficiency [2]. Leadership Statements - Jason Mumper, Founder of Ricochet, expressed enthusiasm about joining Digerati and aims to leverage the acquisition to create significant value [3]. - Robert Delvecchio, Chairman and CEO of Digerati, highlighted the acquisition as a pivotal moment for the company, aiming to utilize Ricochet as a foundational platform for future growth and additional acquisitions [3].

Core Viewpoint - The preliminary valuation of the Baltic Horizon Fund's portfolio indicates a decrease in fair value to EUR 208.7 million from EUR 228.3 million as reported in the interim financial statements as of 30 September 2025 [1]. Group 1 - The fund manager is in the process of finalizing the review of valuation models and will report the final effects along with the NAV of the Fund for the end of November 2025 [2]. - A summary of property valuations will be published on the Fund's webpage following the final report [2].

Core Insights - FEI-Zyfer, Inc. has received two follow-on change orders valued at approximately $4.75 million for the development and manufacture of high-precision airborne time, synchronization, and frequency distribution systems, with deliveries scheduled through 2027 [1] - The airborne-rated systems are designed to operate in high-dynamic environments and are compatible with the latest Assured-Position, Navigation and Timing (A-PNT) and Alternative (Alt-PNT) avionics, supporting collaborative airborne operations [1] - The company emphasizes its investment in developing a revolutionary Rubidium Atomic Clock optimized for demanding airborne applications, claiming unmatched performance in the field-deployable atomic clock market [2] Company Overview - Frequency Electronics, Inc. is a leader in high precision timing, frequency generation, and RF control products for both space and terrestrial applications, serving various sectors including military and commercial systems [3] - The company has received over 100 awards for excellence in providing high-performance electronic assemblies for more than 150 space and Department of Defense programs, highlighting its commitment to research and development [3] - FEI's mission is to transform laboratory discoveries into practical products, focusing on precision time and frequency generation for critical applications [3]